# Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

> **NCT03842163** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 812 (actual)

## Conditions studied

- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

## Interventions

- **DIAGNOSTIC_TEST:** Diagnosis of TTR amyloidosis cardiomyopathy

## Key facts

- **NCT ID:** NCT03842163
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2022-06-08
- **Final completion:** 2022-06-08
- **Target enrollment:** 812 (ACTUAL)
- **Last updated:** 2024-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03842163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03842163, "Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT03842163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*